We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Portable Nucleic Acid Extraction System Developed For POC Diagnostics

By LabMedica International staff writers
Posted on 31 Jul 2013
A portable, pressure driven, room temperature nucleic acid extraction and storage system for point of care (POC) molecular diagnostics has been developed. More...


A minimally instrumented sample preparation technology yields a purified and thermally stabilized nucleic acid sample that eliminates the cold chain without reducing sensitivity or an increase in downstream processing infrastructure.

Biomedical engineers at Boston University (MA, USA) have developed a whole blood compatible, enzyme-free, ambient temperature, low-pressure nucleic acid extraction process that enables the creation of a completely powerless nucleic acid sample preparation technology. This technology will allow, for example human immunodeficiency virus (HIV) viral load monitoring in low resource areas.

A novel hybrid alcohol precipitation and solid phase extraction process has been presented, utilizing glycogen carrier particles to increase the effective hydrodynamic radius of precipitated nucleic acids aggregates, and a thermally polymerized acrylate based solid phase as a weir for analyte capture. An air pressure driven mechanical system was developed to perform this process in a semiautomated fashion, in order to insulate the process from variations in operator technique. Together, they form the System for Nucleic Acid Purification (SNAP).

The portable system for centrifuge-free room temperature nucleic acid extraction from 70 μL of whole blood uses only thermally stable reagents compatible with storage and transport in low resource settings. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis of simulated samples demonstrate a lower limit of detection of 1,000 copies per mL, with the ability to detect differences in viral load across four orders of magnitude.

The device weighs less than 1.36 kg and is capable of extracting HIV-1 viral ribonucleic acid (RNA) directly from virions in whole blood in less than 35 minutes. Samples are stabilized on detachable cartridges, which can be eluted either at the point of care, or transported to a centralized laboratory for further analysis. The study was published on May 13, 2013, in the journal Analytical Methods.

Related Links:

Boston University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gastrointestinal Panel
Xpert® GI Panel
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.